Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum

Vicore Pharma will outline its AT2 receptor agonist pipeline, including buloxibutid for IPF, at a Stifel virtual forum in September 2026.

Rhea-AI Summary

Vicore Pharma (VCRE) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, from 8:30 to 8:55 AM ET.

The virtual event will feature a company presentation and 1×1 meetings with CEO Ahmed Mousa, CFO Hans Jeppsson and CMO Bernt van den Blink. Vicore focuses on angiotensin II type 2 receptor agonists, including its lead oral small molecule buloxibutid for idiopathic pulmonary fibrosis (IPF), which has Orphan Drug and Fast Track designations and is in a global 52‑week Phase 2b ASPIRE trial.

Key Terms

angiotensin II type 2 receptor agonists, orphan drug, fast track, phase 2b, +1 more

5 terms

angiotensin II type 2 receptor agonists medical

"a novel class of drugs, angiotensin II type 2 receptor agonists"

A class of experimental or approved drugs that bind to and activate the angiotensin II type 2 receptor (AT2), a specific protein on cell surfaces involved in regulating blood vessel tone, inflammation, and tissue repair; think of the receptor as a lock and these drugs as keys that turn it on. They matter to investors because successful AT2 agonists can lead to new treatments for cardiovascular, fibrotic, or inflammatory conditions, affecting clinical trial progress, regulatory outcomes, and potential market value.

orphan drug regulatory

"has received Orphan Drug and Fast Track designation"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"has received Orphan Drug and Fast Track designation"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

phase 2b medical

"the global 52-week Phase 2b ASPIRE trial"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

ipf medical

"including idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease where scar tissue builds up in the lungs for reasons doctors don't fully understand, making it harder to breathe over time. For investors, IPF matters because it represents a clear medical need and a regulated market for treatments, so progress in clinical trials, regulatory approvals, or new therapies can materially affect the value of companies working on drugs or devices for this condition—much like a new road that could open access to a previously hard-to-reach town.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists, today announced that the company will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum.

Location: Virtual

Format: Presentation and 1×1 meetings

Presentation Date and Time: Thursday, September 24, 2026, 8:30-8:55 AM ET

Participants: Ahmed Mousa, CEO; Hans Jeppsson, CFO; and Bernt van den Blink, CMO

Webcast: Link

For more information, please contact:

Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Present in the Stifel 2026 Virtual Immunology and Inflammation Forum

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who will represent Vicore Pharma at the Stifel 2026 Virtual Immunology and Inflammation Forum?

Vicore Pharma will be represented by Ahmed Mousa, CEO, Hans Jeppsson, CFO, and Bernt van den Blink, CMO during the presentation and 1×1 meetings.

What is Vicore Pharma’s lead program and its regulatory status?

The company’s lead program is buloxibutid, an oral small molecule angiotensin II type 2 receptor agonist for idiopathic pulmonary fibrosis (IPF). It has received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is being investigated in the global 52‑week Phase 2b ASPIRE trial in IPF.

What is the format and timing of Vicore Pharma’s appearance at the forum?

The forum appearance is virtual and will include a company presentation and 1×1 meetings. The presentation is scheduled for Thursday, September 24, 2026, from 8:30 to 8:55 AM ET.